Acrobiosystems Co., Ltd. Class A

Acrobiosystems Co., Ltd. Class A

SSZSE:301080
74.44
CNY
-1.58
(-2.08%)
1.16EPS
121.19P/E
23.65BMarket Cap
Apr 26Next Earn
Acrobiosystems Co., Ltd. Class A
SZSE:301080
(Shenzhen Stock Exchange)

Recent

price

74.44

P/E

ratio

121.19

div

yld

0.00%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.37
0.42
0.61
1.95
1.77
2.82
3.24
3.84
5.01
6.13
Revenue per Share
0.05
0.07
0.07
0.92
0.8
1.21
0.91
0.74
0.99
1.16
Basic EPS, GAAP
-0.09
-0.01
0.06
0.65
0.35
-0.49
-0.1
-0.49
0.9
- -
Free Cash Flow per Basic Share
- -
- -
- -
0.16
- -
0.71
0.71
0.64
0.51
- -
Dividend per Share
0.48
0.81
0.77
1.59
14.68
15.26
15.41
15.57
15.9
16.38
Book Value per Share
0.48
0.8
0.77
1.58
14.67
15.19
15.19
15.35
15.69
16.18
Tangible Book Value per Share
126
168
168
126
217
168
168
168
167
167
Basic Weighted Avg Shares
47
70
103
246
385
474
544
645
838
1,026
Sales/Revenue/Turnover
16.9
18.02
14.76
56.83
49.87
34.91
24.36
16.95
23.5
25.58
Operating Margin (%)
1
3
4
6
14
34
42
53
68
- -
Depreciation Expense
7
11
11
116
174
204
154
124
166
195
Net Income, GAAP
3.28
5.56
12.49
13.42
11.26
7.34
8.16
3.9
2.65
3.06
Effective Tax Rate (%)
13.82
16.24
10.75
47.05
45.25
42.94
28.25
19.2
19.75
18.98
Profit Margin (%)
45
52
67
150
2,342
2,138
2,042
1,957
1,596
1,469
Working Capital
- -
- -
- -
13
20
53
39
25
68
90
LT Debt
60
73
97
200
2,466
2,569
2,588
2,611
2,658
2,746
Total Equity
- -
16.88
13.09
73.1
12.74
7.77
5.56
4.45
6.01
7.02
Return on Invested Capital (%)
- -
16.97
13.07
73.5
12.97
8.22
6.13
4.85
6.15
7.04
Return on Capital (%)
- -
16.97
13.01
77.85
13.06
8.1
5.96
4.76
6.28
7.26
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
19
19
19
LT Borrowings
57
62
84
LT Finance Leases
7
8
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
167
167
168
Market Capitalization
7,319
8,025
23,654

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,738
1,572
1,654
Cash, Cash Equivalents & STI
1,315
1,073
1,156
Accounts Receivable, Net
113
164
176
Inventories
272
277
271
Total Current Liabilities
131
187
185
Payables & Accruals
- -
- -
- -
ST Debt
19
19
19
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
228.04%
1.8%
Free Cash Flow
- -
-40.61%
-282.49%
Net Income, GAAP
- -
11.4%
33.7%
Sales/Revenue/Turnover
- -
28.54%
29.94%
Total Cash Common Dividend
- -
- -
-20.94%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
146
153
164
182
645
2025
186
201
- -
225
838
2026
236
264
301
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.18
0.16
0.16
0.24
0.74
2025
0.23
0.26
- -
0.2
0.99
2026
0.28
0.31
0.38
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.63
0.02
0.64
2025
0.21
0.01
- -
- -
0.51
2026
- -
- -
- -
- -
- -
Business
Acrobiosystems Co., Ltd. (SZSE: 301080) is a global biotechnology enterprise specializing in the research, development, manufacture, and commercialization of critical biological reagents, assay kits, and analytical solutions for the biopharmaceutical, life science research, and in vitro diagnostics industries. Founded in 2010 and headquartered in Beijing, China, the company operates regional headquarters, research laboratories, and production facilities across China, the United States, Germany, Switzerland, the United Kingdom, and Japan. The company operates through several specialized subsidiaries and business divisions, including ACRODiagnostics, ACROBiosystems AG, ACROBiosystems GmbH, and the bioSeedin biopharmaceutical partnering platform. The company offers an extensive portfolio of life science tools and customized solutions supporting the entire drug development pipeline from early target discovery and preclinical validation to clinical trials and commercial manufacturing. Its primary product and service lines include recombinant proteins, comprising immune checkpoint targets, cytokines, viral antigens, receptor enzymes, membrane proteins, biotinylated proteins, and fluorescent-labeled proteins; high-specificity research and diagnostic antibodies, including anti-idiotypic antibodies, pharmacokinetic assay antibodies, and biosimilar benchmark antibodies; immunoassay kits and detection reagents, including enzyme-linked immunosorbent assay (ELISA) kits, inhibitor screening assays, and immunogenicity test kits; cell engineering and culture reagents, including stable cell lines, reporter gene assays, organoid culture media, transfection reagents, and magnetic beads; specialized product lines and sub-brands, such as Aneuro for neurobiology and neurodegenerative disease research, ClinMax for clinical pathology and translational medicine, Resilient Supply for GMP-grade raw materials, CytoPak, SAFENSURE, ComboX, and GENPower; and comprehensive contract research services, including custom gene synthesis, protein expression and purification, antibody development, molecular interaction analytics via surface plasmon resonance (SPR) and bio-layer interferometry (BLI), and GMP-compliant bioprocess raw material manufacturing. In recent operational and strategic developments, Acrobiosystems has expanded its advanced therapy raw material offerings and global regulatory accreditations. The company obtained Material Suitability Confirmation from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its GMP-grade Interleukin-15 (IL-15), accelerating regulatory clearance pathways for cell therapy developers. Under its Aneuro division, the company entered into a strategic collaboration with Diagnostic Biochips to co-develop and supply integrated in vivo electrophysiology probe systems, neural sensors, and specialized biochemical reagents for neurological drug discovery. Additionally, Acrobiosystems operationalized expanded GMP-grade manufacturing infrastructure and scaled its direct distribution and technical support networks across North America and Europe to support increasing global demand in cell and gene therapy (CGT), antibody-drug conjugate (ADC), and mRNA therapeutic pipelines.